Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Shibata, Masa Aki ^a   Morimoto, Junji ^a   Shibata, Eiko ^a,d   Kurose, Hitomi ^a   Akamatsu, Kanako ^b   Li, Zhong Lian ^a   Kusakabe, Moriaki ^c   Ohmichi, Masahide ^a   Otsuki, Yoshinori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOPLASM; DNA SYNTHESIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPH VESSEL; MALE; METASTASIS INHIBITION; MICROVASCULATURE; MITOCHONDRION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OSMOTIC PUMP; PROTEIN LOCALIZATION; SEX DIFFERENCE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASODILATATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; CELL SURVIVAL; EXPERIMENTAL NEOPLASM; HUMAN; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX FACTORS;

EID: 77957907665     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-566     Document Type: Article

References (44)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90(18):1371-1388. 10.1093/jnci/90.18.1371, 9747868.
2. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995, 87(9):645-651. 10.1093/jnci/87.9.645, 7752269.
3. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361(9354):296-300. 10.1016/S0140-6736(03)12342-2, 12559863.
4. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295(5564):2465-2468. 10.1126/science.1068537, 11923541.
5. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen induced mammary tumors and on LH and prolactin levels. Life Sci 1983, 32(25):2869-2875. 10.1016/0024-3205(83)90323-5, 6406781.
6. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987, 47(15):4020-4024.
7. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996, 88(2):123-125. 10.1093/jnci/88.2.123, 8537973.
8. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa) 2009, 2(1):52-59.
9. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009, 9(1):51-60. 10.1586/14737140.9.1.51, 2785111, 19105706.
10. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama 1999, 281(23):2189-2197. 10.1001/jama.281.23.2189, 10376571.
11. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96(23):1751-1761. 10.1093/jnci/djh319, 15572757.
12. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355(2):125-137. 10.1056/NEJMoa062462, 16837676.
13. Lee WL, Cheng MH, Chao HT, Wang PH. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J Obstet Gynecol 2008, 47(1):24-31. 10.1016/S1028-4559(08)60051-0, 18400579.
14. Kuroishi T, Tominaga S. Epidemiol. Breast Cancer. Jpn J Cancer Chemother 2001, 28:168-173.
15. Shibata MA, Morimoto J, Otsuki Y. Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 2002, 9:16-27. 10.1038/sj.cgt.7700415, 11916241.
16. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004, 25:1887-1898. 10.1093/carcin/bgh201, 15180944.
17. Shibata MA, Morimoto J, Shibata E, Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 2008, 15(12):776-786. 10.1038/cgt.2008.43, 18654613.
18. Shibata MA, Shibata E, Morimoto J, Eid NAS, Tanaka Y, Watanabe M, Otsuki Y. An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging. Anticancer Res 2009, 29:4389-4396.
19. Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandy T, Korsmeyer SJ, Green JE. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999, 18:2692-2701. 10.1093/emboj/18.10.2692, 1171351, 10329616.
20. Yoshimori A, Sakai J, Sunaga S, Kobayashi T, Takahashi S, Okita N, Takasawa R, Tanuma S. Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacol 2007, 7:8. 10.1186/1471-2210-7-8, 1931592, 17594508.
21. Tanuma S, Yoshimori A, Takasawa R. Genomic drug discovery for apoptosis regulation using a new computer screening amino acid complement wave method. Biol Pharm Bull 2004, 27(7):968-973. 10.1248/bpb.27.968, 15256724.
22. Shibata MA, Akao Y, Shibata E, Nozawa Y, Ito T, Mishima S, Morimoto J, Otsuki Y. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol 2007, 60:681-691. 10.1007/s00280-007-0414-y, 17256131.
23. O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006, 12(7 Pt 1):2255-2263. 10.1158/1078-0432.CCR-05-2584, 16609042.
24. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, Maeda M, Furuyama H, Kondo Y, Imamura M. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 2000, 6(5):1647-1654.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
26. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008, 28(1B):479-483. 2610490, 18383888.
27. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643. 10.1038/nrc2713, 19701242.
28. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 2002, 105(11):1368-1373. 10.1161/hc1102.105267, 11901050.
29. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996, 273(5279):1222-1225. 10.1126/science.273.5279.1222, 8703055.
30. Filardo EJ, Quinn JA, Bland KI, Frackelton AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000, 14(10):1649-1660. 10.1210/me.14.10.1649, 11043579.
31. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003, 9(1 Pt 2):502S-510S.
32. Chi A, Chen X, Chirala M, Younes M. Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res 2003, 23(1A):211-216.
33. Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res 2004, 78(4):861-871. 10.1016/j.exer.2003.09.027, 15037120.
34. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407:770-776. 10.1038/35037710, 11048727.
35. Finlay D, Vuori K. Novel noncatalytic role for caspase-8 in promoting SRC-mediated adhesion and Erk signaling in neuroblastoma cells. Cancer Res 2007, 67(24):11704-11711. 10.1158/0008-5472.CAN-07-1906, 18089800.
36. Yao Z, Duan S, Hou D, Heese K, Wu M. Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanism. Embo J 2007, 26(4):1068-1080. 10.1038/sj.emboj.7601571, 1852837, 17290218.
37. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002, 277(37):34287-34294. 10.1074/jbc.M204973200, 12097332.
38. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139411681) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996, 835-842.
39. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997, 177(6):1458-1464. 10.1016/S0002-9378(97)70091-7, 9423751.
40. Flamini MI, Fu XD, Sanchez AM, Giretti MS, Garibaldi S, Goglia L, Pisaneschi S, Tosi V, Genazzani AR, Simoncini T. Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med 2009, 13(8B):2396-2407. 10.1111/j.1582-4934.2008.00505.x, 18798864.
41. Esposito E, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, Meli R. Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 2005, 146(8):3301-3308. 10.1210/en.2005-0375, 15860553.
42. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001, 28(6):536-542. 10.1016/S0093-7754(01)90021-1, 11740806.
43. Doshida M, Ohmichi M, Tsutsumi S, Kawagoe J, Takahashi T, Du B, Mori-Abe A, Ohta T, Saitoh-Sekiguchi M, Takahashi K, et al. Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. J Biol Chem 2006, 281(34):24270-24278. 10.1074/jbc.M513251200, 16798746.
44. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878.